Hypothesis | Open | Published:
Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis
Pediatric Rheumatologyvolume 7, Article number: 18 (2009)
Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that < 20% recognized signs and symptoms of MPS I or could identify appropriate diagnosis tests. These results prompted formation of an international working group of rheumatologists, pediatric rheumatologists, and experts on MPS I to formulate a rheumatology-based diagnostic algorithm. The resulting algorithm applies to all MPS disorders with musculoskeletal manifestations.
Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (laronidase), MPS II (idursulfase), and MPS VI (galsulfase).
Presentation of the hypothesis
Evolving joint pain and joint contractures in the absence of inflammation should always raise the suspicion of an MPS disorder. All such patients should undergo urinary glycosaminoglycan (uGAG) analysis (not spot tests for screening) in a reputable laboratory. Elevated uGAG levels and/or an abnormal uGAG pattern confirms an MPS disorder and specific enzyme testing will determine the MPS type. If uGAG analysis is unavailable and the patient exhibits any other common sign or symptom of an MPS disorder, such as corneal clouding, history of hernia surgery, frequent respiratory and/or ear, nose and throat infections; carpal tunnel syndrome, or heart murmur, proceed directly to enzymatic testing. Refer patients with confirmed MPS to a geneticist or metabolic specialist for further evaluation and treatment.
Testing of the hypothesis
We propose that rheumatologists, pediatric rheumatologists, and orthopedists consider our diagnostic algorithm when evaluating patients with joint pain and joint contractures.
Implications of the hypothesis
Children and young adults can suffer for years and sometimes even decades with unrecognized MPS. Rheumatologists may facilitate early diagnosis of MPS based on the presenting signs and symptoms, followed by appropriate testing. Early diagnosis helps ensure prompt and appropriate treatment for these progressive and debilitating diseases.
Undiagnosed patients with the attenuated form of mucopolysaccharidosis type I (MPS I) often have joint symptoms in childhood that prompt their referral to a rheumatologist, orthopedist, or orthopedic surgeon. Diagnostic delays are unfortunately common for patients with attenuated MPS I, who can suffer for years, sometimes decades, from this progressive and debilitating disease before it is finally recognized [1–4] (Appendix). The advent of enzyme replacement therapy (laronidase, Aldurazyme®, Genzyme Corporation, Cambridge MS) for MPS I in 2003, has enabled a targeted approach in the management of attenuated MPS I. Rheumatologists and musculoskeletal specialists are in a position to recognize the possibility of MPS I, enabling appropriate diagnosis and treatment of affected individuals before development of an irreversible disease stage.
To gauge physician familiarity with the symptoms of MPS I and experience with MPS I patients, Genzyme Corporation conducted a survey of practicing rheumatologists and pediatric rheumatologists in Canada, France, Germany, Italy, Spain, and the United Kingdom . Among the 60 participants, only 9% indicated that they had seen an MPS I patient in their practice; however, an additional 13% indicated that they might have an MPS I patient in their care on the basis of common signs and symptoms. When presented with a description of an 8-year-old girl or a 23-year-old woman exhibiting musculoskeletal signs of MPS I, only 13% of pediatric rheumatologists and 19% of rheumatologists considered MPS I in their differential diagnosis. This percentage increased only slightly or actually declined when additional signs and symptoms of MPS I were added to patient descriptors. Finally, when asked what diagnostic tests should be performed when MPS I is suspected, only 20% of the pediatric rheumatologists and none of the rheumatologists identified appropriate tests. The results of this survey prompted an international working group of rheumatologists, pediatric rheumatologists, and experts on MPS I to formulate a rheumatology-based diagnostic algorithm for MPS I.
Although the algorithm was developed specifically for MPS I, it is also applicable to attenuated forms of all other MPS disorders with the exception of MPS III (Sanfilippo syndrome), which is characterized primarily by CNS manifestations [5–7]. In particular, MPS I and II (Hunter disease) have a very similar clinical presentation, although MPS II occurs primarily in boys as it is inherited in an X-linked recessive manner. MPS II and MPS VI (Maroteaux-Lamy) are also now treatable with enzyme replacement therapy [8, 9].
About MPS I
MPS I is one of the more common mucopolysaccharidoses, a family of seven inherited metabolic diseases caused by deficient activity of various lysosomal enzymes, resulting in the inability to metabolize certain glycosaminoglycans (Table 1). In the case of MPS I, patients have an undetectable activity of the lysosomal enzyme α-L-iduronidase (IDUA). Lack of IDUA activity results in progressive accumulation of the glycosaminoglycans dermatan sulfate and heparan sulfate in lysosomes throughout the body, leading to a multi-systemic disease. Prominently affected organ systems include airways, heart, viscera, skeleton, and (in the most severe cases) the central nervous system. The disease presents across a spectrum of severity, and historically is categorized into three subjectively defined phenotypes. "Hurler syndrome," the most severe form of the disease, begins in infancy, progresses rapidly, and is associated with profound cognitive decline. Untreated children with Hurler syndrome rarely survive beyond age 10 . "Scheie syndrome," the least severe, is characterized by onset in childhood, variable rate of progression and organ involvement, normal intelligence, and survival to adulthood. "Hurler-Scheie syndrome" encompasses patients with onset in early childhood, mild to moderate CNS involvement, and an intermediate rate of progression and organ involvement. Clinical heterogeneity is especially prominent in the less severe end of the spectrum, and Hurler-Scheie and Scheie presentations are often grouped together and referred to as "attenuated MPS I."
Patients with attenuated MPS I, unlike those with the severe, "Hurler" form of the disease, often have no obvious physical abnormalities; facial appearance is usually normal or only subtly altered, stature can be in the normal range, and skeletal abnormalities are often absent or subclinical. Learning issues, if present, can be mild. Common early clinical features include joint pain and stiffness, corneal clouding, umbilical and/or inguinal hernia, carpal tunnel syndrome (note that an MPS disorder is the most frequent cause of carpal tunnel syndrome in children and adolescents [12, 13]), hearing loss, frequent ear, nose and throat infections, and "noisy" breathing. Musculoskeletal abnormalities that can occur later in the disease course include progressive arthropathy, hip dysplasia, dysostosis multiplex, spine deformities, and spinal cord compression. Cardiac valve disease is also very common.
As shown in Table 1, the major clinical manifestations of attenuated MPS I are similar to those of MPS II, MPS VI, and MPS VII (Sly syndrome). MPS IV, Morquio syndrome, is characterized by a distinctive and severe skeletal dysplasia, dysplastic odontoid process, and hyperextendable joints/ligamentous laxity rather than joint contractures . All of the MPS disorders occur across a spectrum of severity, and diagnosis is often challenging for those with the less severe forms of the disease.
Joint Symptoms in MPS I
Joint symptoms in MPS I patients are almost universal, and in the case of attenuated disease are often the first symptom that brings a child to medical attention [1, 2]. In the MPS I Registry, an ongoing, observational database that tracks natural history and outcomes of patients with MPS I, joint contractures are reported in over 80% of Hurler-Scheie and Scheie patients and usually precede diagnosis .
The basis for the abnormal development of bone and cartilage seen in the MPS disorders is not fully understood. Although the absence of clinical signs of inflammation is a hallmark of joint involvement in the MPS disorders, investigations conducted in animal models suggest paradoxically that the pathophysiology of bone disease involves inflammatory cytokines such as tumor necrosis factor α and interleukin-1β in addition to proteins important for lipopolysaccharide signaling (e.g., Toll-like receptor 4 and lipoprotein-binding protein) [15–17].
Presentation of the Hypothesis
To aid rheumatologists and other physicians in the differential diagnosis of MPS I and other MPS disorders, a diagnostic algorithm is proposed (Figure 1), which was drafted at a one-day meeting attended by all authors. Joint contractures were chosen as a starting point in the algorithm because they are an early and almost universal symptom among MPS patients with attenuated disease. In summary, joint pain and joint contractures in the absence of systemic and local signs of inflammation should always raise the suspicion of an MPS disorder, especially in concert with any other common sign or symptom of MPS. Note that in cases of juvenile idiopathic arthritis characterized by "dry arthritis," joints usually lack synovial effusions, but patients may display other signs of an inflammatory process, such as frequent fevers and/or high erythrocyte sedimentation rate . In contrast, MPS patients typically have no swelling or local inflammation of any joints, no morning stiffness, no laboratory indicators of inflammation (erythrocyte sedimentation rate, C-reactive protein, and white blood cell counts are not elevated), no response to steroids or non-steroidal anti-inflammatory drugs, and no radiographic evidence of erosive bone lesions (Figure 2 and 3). Indeed, the problems are persistent and often progress, particularly in patients not on enzyme therapy.
When MPS I or other MPS disorder is suspected, a urinary glycosaminoglycan (uGAG) analysis (both quantitative and qualitative) should be performed at a reputable laboratory. We do not recommend a spot screen, as they are inaccurate and false negatives can occur. An elevated uGAG level is a strong indicator of an MPS disorder; however, a normal uGAG level does not rule out all forms of MPS, some of which are best identified by an abnormal uGAG profile [6, 7, 19]. An elevated uGAG level and/or an abnormal uGAG pattern confirms the presence of an MPS disorder and specific enzyme testing will determine the MPS type. If comprehensive uGAG analysis is not available, enzymatic testing should still be performed if the patient exhibits any other common sign or symptom of an MPS disorder, such as corneal clouding (Figure 4) or history of hernia surgery, frequent respiratory and/or ear, nose and throat infections, carpal tunnel syndrome, or heart murmur. Table 1 lists the specific enzyme deficiency characteristic of each disorder. A definitive diagnosis of MPS I is based on deficient IDUA activity in fibroblasts, leukocytes, serum, or blood spots [20, 21].
Patients with confirmed MPS should be referred to a geneticist or metabolic specialist for further evaluation and treatment. All of the MPS disorders are multisystemic and progressive and are best managed by a multidisciplinary team with comprehensive followup [5, 10, 22]. Both disease-specific treatment as well as symptom-based supportive care are important, in addition to patient education, genetic counseling, psychosocial support, and physical and/or occupational therapy. MPS patients can have significant (and often under-recognized) airway problems and cervical spine issues such as spinal cord compression that increase risk of anesthetic complications; thus, appropriate precautions should be taken before any surgery.
Disease-specific care for patients with attenuated MPS I consists of enzyme replacement therapy with laronidase (0.58 mg/100 U per kg per week). Available enzyme replacement therapies for the other MPS diseases with musculoskeletal manifestations are listed in Table 1. As with any progressive metabolic disease, early initiation of therapy that addresses the underlying pathophysiology improves outcome, and can prevent or at least delay the development of irreversible disease manifestations. Clinical trials of laronidase in patients with attenuated MPS I have demonstrated improved respiration, decreased hepatomegaly, increased walking ability, enhanced joint range of motion, and improved quality of life [23–26]. Hematopoietic stem cell transplantation (HSCT) is recommended for patients with severe MPS I, if performed before age 2 as it can prolong life and preserve cognition, but is not recommended for patients with attenuated MPS I, because they have little or no cognitive involvement, making the procedural risk-benefit ratio unacceptable (10-15% mortality) . HSCT is used much less frequently in other MPS disorders and only among severely affected patients and transplant outcome has been mixed [7, 27–29].
Testing of Hypothesis
We propose that clinicians, particularly rheumatologists, pediatric rheumatologists, and orthopedists use our diagnostic algorithm when evaluating any patient with joint pain, stiffness or contractures and no systemic and local signs of inflammation. The index of suspicion for MPS should be especially high if the patient also has a history of hernia surgery, frequent respiratory infections, corneal clouding, carpal tunnel syndrome, or cardiac valvular abnormalities.
Implications of Hypothesis
Attenuated MPS disorders can present a diagnostic challenge because the symptoms are often subtle and/or non-specific. Rheumatologists, and especially pediatric rheumatologists, are uniquely positioned to recognize many patients with attenuated MPS because of their characteristic joint involvement. Use of the proposed diagnostic algorithm should improve disease recognition, and enable more patients to receive appropriate treatment earlier in the course of their disease, maximizing clinical outcome and enhancing patient quality of life.
Written informed consent was obtained from the patient for publication of the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Connective tissue disease
Juvenile idiopathic arthritis
Other systemic rheumatic disorder
hematopoietic stem cell transplantation
Vijay S, Wraith JE: Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005, 94: 872-877. 10.1080/08035250510031584.
Cimaz R, Vijay S, Haase C, Coppa GV, Bruni S, Wraith E, Guffon N: Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin Exp Rheumatol. 2006, 24: 196-202.
Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE: The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab. 2007, 91: 37-47. 10.1016/j.ymgme.2007.01.011.
Manger B: Rheumatological manifestations are key in the early diagnosis of mucopolysaccharidosis type I. European Musculoskeletal Review. 2008, 1-6.
Northover H, Cowie RA, Wraith JE: Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996, 19: 357-365. 10.1007/BF01799267.
Neufeld EF, Muenzer J: The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver C, et al. 2001, New York: McGraw Hill, 3421-3452.
Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Muñoz V, Muenzer J: Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008, 121: e377-386. 10.1542/peds.2007-1350.
Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A: A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007, 90: 329-337. 10.1016/j.ymgme.2006.09.001.
Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ, MPS VI Phase 3 Study Group: Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006, 148: 533-539. 10.1016/j.jpeds.2005.12.014.
Muenzer J, Wraith JE, Clarke LA: Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009, 123: 19-29. 10.1542/peds.2008-0416.
Murphy AM, Lambert DM, Treacy EP, O'Meara A, Lynch SA: Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish Republic. Arch Dis Child. 2009, 94: 52-54. 10.1136/adc.2007.135772.
Lamberti PM, Light TR: Carpal tunnel syndrome in children. Hand Clin. 2002, 18: 331-337. 10.1016/S0749-0712(01)00010-5.
Van Meir N, De Smet L: Carpal tunnel syndrome in children. Acta Orthop Belg. 2003, 69: 387-395.
Bodamer OA: Clinical characteristics of MPS I patients in the MPS I Registry. Presented at The American Society of Human Genetics. 2007, San Diego, California, [http://www.ashg.org/genetics/ashg07s/index.shtml]October
Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP: Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005, 69: 589-595. 10.1016/j.ijporl.2005.01.017.
Simonaro C, D'Angelo M, Haskins M, Schuchman E: Joint and bone disease in the mucopolysaccharidoses: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res. 2005, 57: 701-707. 10.1203/01.PDR.0000156510.96253.5A.
Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH: Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2008, 172: 112-122. 10.2353/ajpath.2008.070564.
Ostrov BE: What is the significance of dry synovitis?. Pediatric Rheumatology Online Journal. 2004, 2: 114-118.
Piraud M, Boyer S, Mathieu M, Maire I: Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glycosaminoglycan analysis: a study of 2,000 urine samples. Clin Chim Acta. 1993, 221: 171-181. 10.1016/0009-8981(93)90031-X.
Hall CW, Liebaers I, Di Natale P, Neufeld EF: Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 1978, 50: 439-456. full_text.
Chamoles NA, Blanco MB, Gaggioli D, Casentini C: Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001, 47: 2098-2102.
Muenzer J: The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004, 144: S27-34. 10.1016/j.jpeds.2004.01.052.
Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R, Neufeld EF: Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001, 344: 182-188. 10.1056/NEJM200101183440304.
Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004, 144: 581-588. 10.1016/j.jpeds.2004.01.046.
Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, Okazaki S, Huff K, Cox GF, Swiedler SJ, Kakkis ED: A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007, 90: 171-180. 10.1016/j.ymgme.2006.08.007.
Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009, 123: 229-240. 10.1542/peds.2007-3847.
Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R: Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr. 2009, 154: 733-737. 10.1016/j.jpeds.2008.11.041.
Lee V, Li CK, Shing MM, Chik KW, Lam CW, Tsang KS, Pong H, Huen KF, Yuen PM: Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant. 2000, 26: 455-458. 10.1038/sj.bmt.1702528.
Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, Kojima S, Matsuyama T, Sly WS, Kondo N, Orii T: Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1998, 21: 629-634. 10.1038/sj.bmt.1701141.
Schiro JA, Mallory SB, Demmer L, Dowton SB, Luke MC: Grouped papules in Hurler-Scheie syndrome. J Am Acad Dermatol. 1996, 35: 868-870. 10.1016/S0190-9622(96)90107-3.
The authors thank Genzyme Corporation for covering the costs of the publication and the face-to-face meeting of the authors and Lisa Underhill (Genzyme Global Medical Affairs) for providing medical writing assistance. Genzyme Corporation had no substantive role in formulating the hypothesis, the drafting of the algorithm, proposing treatment recommendations, or making the decision to submit the manuscript for publication.
All authors received honoraria from Genzyme Corporation for attending the meeting at which the algorithm was drafted. In addition, RC has received reimbursement for travel expenses from Genzyme; GVC has received reimbursement for travel expenses and honoraria for presentations and advisory board meetings, BM has a consultancy agreement with Genzyme, GP is a recipient of research funding from Genzyme, and NW has received reimbursement for travel expenses and consultancy agreements from Genzyme. No other author has declared competing interests.
An initial version of the algorithm was drafted by RC. BM chaired the meeting. All authors contributed equally to the development of the text, the revision of the algorithm, and the decision to submit to Pediatric Rheumatology. All authors have read and approved the final manuscript.